top of page

ViroCure is developing multiple virus platforms for cancer therapeutics & vaccine development.

Our viruses selectively infect and kill cancer cells, and activate anti-cancer immune responses. Our technology replicates profusely in cancer cells, with negligible effects on normal cells.
RC402

A naturally occuring reovirus originally isolated from a healthy child, which pre-clinical studies have shown to be highly effective at fighting metastatic tumors (RC402).

​

  • Proven to be long-lasting, safe, & stable for human subjects

  • Improved cytopathic effect without additional arming in select tumor types

  • Anti-angiogenic effect to kill tumors

  • Applicable for both local and systemic administration

  • Usage patent granted in Korea, China, & Japan

  • Clinical trial currently underway in Australia for liver-metastasized solid tumors

RP116

A naturally occuring reovirus which preliminary research has shown to be highly effective at fighting oral cancers, salivary gland cancer, soft tissue sarcoma, melanoma, etc. (RP116)

​

  • First-in-the-world, proprietary oncolytic virus with modification of sigma1, a major immunogenic capsid protein of RC402​​

  • Systemic administration with a potent tumor killing activity

  • Applicable to immuno-competent and compromised tumor patients, e.g. pregnant women, children, AIDS patients, etc.

  • Patents granted in the USA / Challenge to global market

MC509

A naturally occuring rabbit-specific poxvirus, originally isolated from a Brazillian rabbit species. Not known to cause diseases outside of rabbit species. In pre-clinical studies, MC509 has been highly oncolytic against tumor-bearing animals. 

​

  • Engineered, multi-armed oncolytic virus

    • Systemic administration possible without generating neutralizing antibodies

  • Using gene editing to create new viral agents

    • Manipulation of tumor micro-environment for immune evasion, boosting, etc.

    • Creation of cancer vaccines

  • Targets global pharma for licensing-out & partnership

SC717

A naturally occuring squirrel-specific poxvirus originally isolated from a grey squirrel. Not known to cause diseases outside of squirrel species. In pre-clinical studies, SC717 has been highly oncolytic against tumor-bearing animals.

​

  • Oncolytic viral activity discovered and patented by Virocure

  • Systemic administration possible without generating neutralising antibody

  • Using gene editing to create new viral agents

    • Manipulation of tumor micro-environment for immune evasion, boosting, etc.

    • Creation of cancer vaccines

  • Targeting global pharma for licensing-out & partnership

Development Pipeline

Virus Platform                Discovery Research                Preclinical                Phase I                Phase II/III

Short-term

RC402-IT                   Liver metastatic solid cancer (colon, etc.)                                       

ICI combination treatment, intratumor administration (IT). Australia clinical trial 1B in progress.

MC509-N1                 CRC, Lung cancer                                                   

Single/combination IT/intravenous (IV). MSS type CRC w/ poor prognosis; Target group of patients w/ low PD-L1 expression rate.

RC402-PO                 CRC                                                                            

Single/combination oral administration. (PO). World's first oral anticancer drug.

NK cell + OV              Bladder Cancer                                     

NK cells, IT/IV. Innovative BCG Immunotherapy.

Mid-term

MC509-N2/N3         CRC, Rare cancers                  

New patient-specific manufacturing materials.

RP116-M                     Cancer vaccine                                     

Innovative drugs for cancer treatment, diagnosis, & prevention.

Last updated 26 Feb 2022

bottom of page